UBS lowered the firm’s price target on Hologic (HOLX) to $84 from $90 and keeps a Neutral rating on the shares. The firm updated models in the life science sector following management meetings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Hologic initiated with a Peer Perform at Wolfe amid near-term headwinds
- Hologic initiated with a Peer Perform at Wolfe Research
- Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink
- USPSTF draft guidance on cervical cancer positive for Hologic, says BTIG
Questions or Comments about the article? Write to editor@tipranks.com